托伐普坦片Tolvaptan治疗低钠血症疗效显著

Tolvaptan tablets Tolvaptan is an oral, selective vasopressin antagonist, which is mainly used to treat hyponatremia caused by congestive heart failure, cirrhosis, and antidiuretic hormone deficiency syndrome. It can increase the concentration of sodium ions in the plasma and help excess water be excreted from the urine. In clinical studies, it significantly increased sodium ion concentrations in patients' plasma compared with placebo.

A clinical trial verified the efficacy and safety of Tolvaptan tablets in treating patients with hyponatremia caused by cirrhosis and ascites. In this trial, a total of 40 patients with hyponatremia due to liver cirrhosis and ascites were treated with Tolvaptan tablets. The trial results show that oral Tolvaptan tablets are significantly better than the placebo group in treating cirrhosis and ascites hyponatremia. Tolvaptan tablets can significantly increase the serum sodium concentration in patients with liver cirrhosis and have significant effects on patients with hyponatremia. There are no serious complications and adverse reactions, and it is simple and safe in clinical application. It can be seen that Tolvaptan tablets can reduce the pain of patients, have a positive effect on the patient's condition, and have a significant therapeutic effect.

Precautions for Tolvaptan Tablets

In animal experiments, cleft palate, short limbs, microphthalmia, skeletal deformities, embryonic death and other conditions occurred after treatment with this drug. Therefore, pregnant women should not use Tolvaptan tablets for treatment without authorization. The distribution of tolvaptan tablets in breast milk is unknown, so breast-feeding patients should consider taking the drug or discontinuing breastfeeding.

Diabetic patients with elevated blood glucose concentrations may develop pseudohyponatremia. Therefore, patients should undergo examinations to rule out this condition before and during treatment with Tolvaptan tablets.

Urinary output must be ensured when using Tolvaptan tablets. Patients with difficulty urinating (such as patients with prostatic hypertrophy or urinary disorders) have an increased risk of acute urinary retention. Patients should pay attention to this when receiving treatment.

When using Tolvaptan tablets, attention should be paid to drug interactions. This drug cannot be used in combination with strong CYP3A inhibitors (for example: ketoconazole, itraconazole, ritonavir, indinavir, nifinavir, etc.). If patients are taking other medications, they should inform their doctor before taking Spegra, and a professional doctor will judge whether they can be taken at the same time.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: